Results 171 to 180 of about 38,893 (219)

Comparative effectiveness of missed dose protocols of opioid agonist treatment in British Columbia, Canada: protocol for a population-based target trial emulation. [PDF]

BMJ Open
Mondol MH, Min JE, Kurz M, Zanette M, Hossain MB, Bach P, Gustafson P, Platt RW, Seaman S, Socías ME, Nosyk B, Karim ME.   +11 more
europepmc   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, Volume 183, Issue 14, Page 4058-4071, July 2026.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Comparative effectiveness of take-home dosing schedules for opioid agonist treatment in British Columbia, Canada: a target trial emulation protocol using a population-based observational study. [PDF]

BMJ Open
Kurz M, Guerra-Alejos BC, Hossain MB, Min JE, Yan R, Bruneau J, Catherine NLA, Greenland S, Gustafson P, Hedden L, Karim E, McCandless L, Nolan S, Platt RW, Bach P, Seaman S, Siebert U, Socías ME, Nosyk B.   +18 more
europepmc   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, Volume 183, Issue 14, Page 4022-4047, July 2026.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Health, Social and Recidivism Outcomes Among People Who Have Been Incarcerated in New South Wales, Australia: Study Protocol and Cohort Profile for the Prison Outcomes STudy (POST)

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction We have been funded to examine post‐incarceration health and social outcomes for all people incarcerated in New South Wales, Australia, 2000–2022; assess treatment and services for drug dependence and serious mental illness; and project the impact of expanding intervention coverage. We will use a linked cohort, the Prison Outcomes
Louisa Degenhardt, Michael Farrell, Michael Doyle, Jack Stone, Chrianna Bharat, Matt Hickman, Marianne Martinello, Don Weatherburn, Kimberlie Dean, Joe Coyte, Christel Macdonald, Mary Ellen Harrod, Luke Grant, Gloria Larman, Peter Vickerman, Colette McGrath, Peter Thompson, Alison Churchill, Greg Dore, Thomas Santo Jr   +19 more
wiley   +1 more source

Primary care physician characteristics associated with becoming opioid agonist treatment prescribers in British Columbia: a retrospective case-control study. [PDF]

Harm Reduct J
Panagiotoglou D, Peterson S, Lavergne MR, Gomes T, Chadha R, Johnson C, McCracken R.   +6 more
europepmc   +1 more source

Prevalence and Correlates of Reporting a Gabapentin Prescription for Pain Among People Who Use Opioids: A Longitudinal Community‐Recruited Study

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Gabapentin is widely prescribed off‐label to treat pain. However, there are concerns about the proliferation of medical and non‐medical use, and the potential increased risk of overdose death associated with concurrent opioid use.
Evelyne Marie Piret, Heather Palis, Alexis Crabtree, JinCheol Choi, Kora DeBeck, Kanna Hayashi, Michael R. Law, M.‐J. Milloy   +7 more
wiley   +1 more source

Barriers and facilitators to injectable opioid agonist treatment engagement within a structural vulnerability context: a qualitative study of patient experiences in Vancouver, Canada. [PDF]

Harm Reduct J
Mayer S, Fairbairn N, Fowler A, Boyd J, Kerr T, McNeil R.   +5 more
europepmc   +1 more source

Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain‐Related Outcomes Among People With Non‐Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction In addition to their use as opioid agonist therapy (OAT), methadone and buprenorphine/naloxone also have analgesic properties. However, there is limited information on the relative effectiveness of these medications for analgesia in the context of treatment for non‐heroin opioid use disorder (OUD).
Katie Lyman, JinCheol Choi, Didier Jutras‐Aswad, Bernard L. E. Foll, Sukhpreet Klaire, M. Eugenia Socias   +5 more
wiley   +1 more source

Desirable treatment or a problematic drug scene? - An interview study of patients' and professionals' views on the risks and benefits of liberalized opioid agonist treatment. [PDF]

Harm Reduct J
Nordgren J, Richert T.
europepmc   +1 more source